Rabbits were a standard model for sleep and EEG work of the period, and their size permits collection of cerebral venous blood.

Does intraventricular administration reflect normal physiology?

Not closely. It bypasses the blood-brain barrier and delivers directly to a compartment, at concentrations endogenous signalling may never produce.

DSIP (Delta Sleep-Inducing Peptide)

How DSIP Was Discovered

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected cerebral venous blood draining from the brain, and isolated a peptide fraction from it. Administered to awake rabbits it was reported to produce delta-wave EEG activity. Published in PNAS, March 1977.

Key facts

Group: Schoenenberger–Monnier, Basel
Isolation published: PNAS, March 1977 (PMID 265572)
Sequence published: Pflügers Arch, 1978 (PMID 568769)
Source material: Rabbit cerebral venous blood
Induction method: Electrical thalamic stimulation
Assay route: Intraventricular administration
Endpoint: Delta-wave EEG activity

The reasoning behind the experiment

The design rests on a specific hypothesis: that sleep is induced by a circulating humoral factor. If so, blood leaving the brain of a sleeping animal should carry more of it than blood leaving an awake one, and transferring that blood should transfer the state. This is a coherent idea with a long history in physiology, and the experiment is a direct test of it.

How it was done

The thalamus of a rabbit was electrically stimulated to induce sleep. Blood draining from the brain was collected — cerebral venous blood specifically, because the point was to capture what the brain had released rather than what was arriving. A peptide fraction was isolated from that blood and administered into the cerebral ventricles of awake rabbits, where it was reported to produce the slow delta-wave EEG pattern of deep sleep.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

Then the sequence

The 1978 paper in Pflügers Archiv reported amino-acid analysis, sequence determination, synthesis and activity of the nonapeptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Synthesising the peptide and reproducing the activity was the correct next step, and it is what elevated DSIP from an uncharacterised fraction to a defined molecule.

What the method could not rule out

Cerebral venous blood contains a great deal besides any putative sleep factor. Isolating a peptide fraction that produces an EEG change does not establish that the peptide is what the brain releases to produce sleep, nor that it acts through a physiological pathway rather than a pharmacological one at the concentrations delivered. Intraventricular administration in particular bypasses every normal barrier and delivers to a compartment endogenous signalling may never reach at that concentration.

Judging it fairly

By the standards of 1977 this was careful, imaginative work, and the group followed isolation with sequencing and synthesis rather than stopping at a suggestive fraction. The problem is not the original research. It is that the field never completed the steps that would have converted a promising observation into established biology, and the name has carried an unearned confidence in the meantime.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why rabbits?: Rabbits were a standard model for sleep and EEG work of the period, and their size permits collection of cerebral venous blood.
Was the peptide synthesised and retested?: Yes. The 1978 Pflügers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide, which was the right way to confirm the isolated fraction.
Does intraventricular administration reflect normal physiology?: Not closely. It bypasses the blood-brain barrier and delivers directly to a compartment, at concentrations endogenous signalling may never produce.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum